2-Methoxy-N-(2-morpholinoethyl)acetamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 2-Methoxy-N-(2-morpholinoethyl)acetamide
• 英文别名: 2-methoxy-N-(2-morpholin-4-ylethyl)acetamide
• 化学式: C₉H₁₈N₂O₃
• mdl: MFCD08680006
• 分子量: 202.25
• InChiKey: DQOPBICHYOAKBW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.888
• 拓扑面积：
  50.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Triazole derivatives useful as Axl inhibitors
  申请人：Singh Rajinder

  公开号：US20070213375A1

  公开（公告）日：2007-09-13

  Triazole derivatives and pharmaceutical compositions containing the derivatives are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the derivatives in treating diseases or conditions associated with Axl catalytic activity are also disclosed.

  本发明揭示了三唑衍生物及含有该衍生物的制药组合物，其在抑制受体蛋白酪氨酸激酶Axl的活性方面具有有用性。本发明还揭示了使用该衍生物治疗与Axl催化活性相关的疾病或病况的方法。
• TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS
  申请人：Singh Rajinder

  公开号：US20110082131A1

  公开（公告）日：2011-04-07

  Methods of using triazole derivatives in treating diseases or conditions associated with Axl catalytic activity are disclosed.

  本发明揭示了使用三唑衍生物治疗与Axl催化活性相关的疾病或病症的方法。
• Selective inhibitors of gentotoxic steress-induced IKK/NF-κB pathways
  申请人：Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft

  公开号：US11028084B2

  公开（公告）日：2021-06-08

  A method is for treatment of a disease associated with genotoxic stress-induced inhibitor of nuclear factor-κB kinase/nuclear factor kappa-light chain enhancer of activated B cells (IKK/NF-κB) signaling. The method can include administering a compound to a subject having a cancer exhibiting genotoxic stress induced IKK/NF-κB activation.

  一种方法用于治疗与基因毒性应激诱导的核因子-κB激酶/活化B细胞的核因子卡巴轻链增强子（IKK/NF-κB）信号转导抑制有关的疾病。该方法可包括向患有基因毒性应激诱导的IKK/NF-κB活化的癌症的受试者施用一种化合物。
• AMINOPYRONES AND THEIR USE AS ATM INHIBITORS
  申请人：Kudos Pharmaceuticals Limited

  公开号：EP1654257B1

  公开（公告）日：2010-03-17
• SELECTIVE INHIBITORS OF GENTOTOXIC STERESS-INDUCED IKK/NF-KB PATHWAYS
  申请人：Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft

  公开号：US20190276452A1

  公开（公告）日：2019-09-12

  A method is for treatment of a disease associated with genotoxic stress-induced inhibitor of nuclear factor-κB kinase/nuclear factor kappa-light chain enhancer of activated B cells (IKK/NF-κB) signaling. The method can include administering a compound to a subject having a cancer exhibiting genotoxic stress induced IKK/NF-κB activation.